<DOC>
	<DOCNO>NCT02954016</DOCNO>
	<brief_summary>To evaluate safety efficacy endoscopically implant ValenTx EndoPass™ System treatment adult severe obesity . The EndoPass System indicate weight loss adult body mass index ( BMI ) ≥35 ≤ 50 kg/m2 fail conservative weight loss method .</brief_summary>
	<brief_title>The ePass Clinical Trial Treatment Obese Subjects</brief_title>
	<detailed_description>- Single-arm , multi-center study conduct 50 subject 5 site . - Subjects implanted EndoPass device 36 month . - Body weight , adverse event device function monitor monthly visit first year implant quarterly visit thereafter . - Additional follow-up data include vital sign , hip waist circumference , blood lab test , endoscopic esophagram assessment condition implant device , quality life eat behavior questionnaire . - All subject follow 12 month device removal . - A single device renewal may take place need initial implant . - Subject study participation may last four year , expect vary implant duration , determine case-by-case basis .</detailed_description>
	<criteria>Key 1860 year age . BMI ≥ 35 ≤ 50 kg/m2 Documented failure nonsurgical weight loss method Selfreported maximum minimum body weight past 12 month within 10 % current body weight Key Pregnancy intention become pregnant . Past history esophageal , gastric bariatric surgery . Medical condition contraindicate elective endoscopic bariatric procedure . Insulindependent diabetes mellitus</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>Obesity</keyword>
	<keyword>Weight Loss</keyword>
	<keyword>Hypertension</keyword>
	<keyword>Type 2 Diabetes Mellitus</keyword>
	<keyword>Hyperlipidemia</keyword>
</DOC>